LamdaGen is a private nano-based technology platform company who is the first to produce commercial LSPR (Localized Surface Plasmon Resonance) products. The products include highly sensitive nano-biosensors for In Vitro Diagnostics, including Central Laboratory based and Point of Care testing for human, veterinary and farm animal health. The nanotechnology platform is also purposed for additional scientific applications and products including drug discovery and development, life science research, food and water safety, environmental and contaminant monitoring, and numerous clean technologies.
LamdaGen’s Plasmonic ELISA™ platform is ideally suited for In-Vitro and POC diagnostic systems, facilitating precise quantitation into the low femtomolar range. The Company licenses its Plasmonic Platform technologies to diagnostic companies for integration into their IVD, POC and mobile systems.
Headquartered in Menlo Park, CA, the Company’s products are based upon its patented LSPR surface technologies which produce highly robust sensors and sensor chips in the form of metallic thin films – and are the heart of the Company’s plasmonic platforms and LightPath™ analytical systems.